Of interest, AC220 showed activity also in FLT3 wild-type AML, with composite complete remission responses of about 30%, in the initial trials in relapsed/refractory AML patients (50, 51); the QUANTUM-First frontline randomized phase III multinational study of induction therapy (3 + 7) with AC220 versus placebo in frontline FLT3-ITD AML patients completed enrollment late 2020 and final results are expected late 2021 (NCT02668653). Here, FLT3 is linked to acute myeloid leukemia.